Gastrointestinal stromal tumor
- PDF / 663,056 Bytes
- 9 Pages / 610 x 792 pts Page_size
- 36 Downloads / 227 Views
Open Access
Review
Gastrointestinal stromal tumor Michael Stamatakos*1, Emmanouel Douzinas2, Charikleia Stefanaki1, Panagiotis Safioleas1, Electra Polyzou1, Georgia Levidou3 and Michael Safioleas1 Address: 14th Department of Surgery, University of Athens, School of Medicine, Attikon General Hospital, Athens, Greece, 23rd Department of Critical Care, Athens University, Eugenidion Hospital, Athens, Greece and 3Department of Pathology, School of Medicine, University of Athens, Greece Email: Michael Stamatakos* - [email protected]; Emmanouel Douzinas - [email protected]; Charikleia Stefanaki - [email protected]; Panagiotis Safioleas - [email protected]; Electra Polyzou - [email protected]; Georgia Levidou - [email protected]; Michael Safioleas - [email protected] * Corresponding author
Published: 1 August 2009 World Journal of Surgical Oncology 2009, 7:61
doi:10.1186/1477-7819-7-61
Received: 6 April 2009 Accepted: 1 August 2009
This article is available from: http://www.wjso.com/content/7/1/61 © 2009 Stamatakos et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: GISTs are a subset of mesenchymal tumors and represent the most common mesenchymal neoplasms of GI tract. However, GIST is a recently recognized tumor entity and the literature on these stromal tumors has rapidly expanded. Methods: An extensive review of the literature was carried out in both online medical journals and through Athens University Medical library. An extensive literature search for papers published up to 2009 was performed, using as key words, GIST, Cajal's cells, treatment, Imatinib, KIT, review of each study were conducted, and data were abstracted. Results: GIST has recently been suggested that is originated from the multipotential mesenchymal stem cells. It is estimated that the incidence of GIST is approximately 10-20 per million people, per year. Conclusion: The clinical presentation of GIST is variable but the most usual symptoms include the presence of a mass or bleeding. Surgical resection of the local disease is the mainstay therapy. However, therapeutic agents, such as Imatinib have now been approved for the treatment of advanced GISTs and others, such as everolimus, rapamycin, heat shock protein 90 and IGF are in trial stage demonstrate promising results for the management of GISTs.
Background GISTs (Gastrointestinal tumors) are a subset of mesenchymal tumors and represent the most common mesenchymal neoplasms of GI (Gastrointestinal) tract. Gastrointestinal stromal tumors are KIT-expressing and KIT (tyrosine kinase receptor - CD117)-signaling driven mesenchymal tumors. Many GIST tumors have an activating mutation in either KIT or PDGFR (Platelet-Derived
Growth Factor Receptor Alpha) [1]. They account for
Data Loading...
